Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of CT1812 in mild to moderate Alzheimer's disease
2022-002326-27Phase 2Completed
- Sponsor
- Cognition Therapeutics, Inc.
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zervimesine in Alzheimer's disease (AD) (3 arms), sponsored by Cognition Therapeutics, Inc. Primary endpoints: Safety endpoints and Target engagement and pharmacodynamic effects in CSF. Started Jul 2022; status: completed.
02
Drugs
zervimesine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2022-002326-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002326-27.